Sage Therapeutics, Inc. (NASDAQ:SAGE) had its price objective hoisted by equities researchers at Royal Bank Of Canada from $117.00 to $120.00 in a report released on Thursday. Royal Bank Of Canada’s target price would suggest a potential upside of 89.63% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on SAGE. Stifel Nicolaus reissued a “buy” rating and issued a $90.00 price objective on shares of Sage Therapeutics in a research report on Friday, July 14th. BMO Capital Markets reissued a “buy” rating and issued a $82.00 price objective on shares of Sage Therapeutics in a research report on Friday, July 28th. BidaskClub cut Sage Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. HC Wainwright increased their price objective on Sage Therapeutics to $86.00 and gave the company a “neutral” rating in a research report on Friday, August 4th. Finally, Needham & Company LLC set a $95.00 price objective on Sage Therapeutics and gave the company a “buy” rating in a research report on Friday, August 4th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $86.71.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($1.98) by $0.01. Sage Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: “Royal Bank Of Canada Boosts Sage Therapeutics, Inc. (SAGE) Price Target to $120.00” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/11/02/royal-bank-of-canada-boosts-sage-therapeutics-inc-sage-price-target-to-120-00.html.

Hedge funds have recently modified their holdings of the stock. Parametric Portfolio Associates LLC raised its stake in Sage Therapeutics by 31.2% during the first quarter. Parametric Portfolio Associates LLC now owns 24,576 shares of the biopharmaceutical company’s stock worth $1,747,000 after acquiring an additional 5,842 shares in the last quarter. Principal Financial Group Inc. raised its stake in Sage Therapeutics by 1.1% during the first quarter. Principal Financial Group Inc. now owns 5,623 shares of the biopharmaceutical company’s stock worth $400,000 after acquiring an additional 62 shares in the last quarter. Teachers Advisors LLC raised its stake in Sage Therapeutics by 139.5% during the first quarter. Teachers Advisors LLC now owns 118,072 shares of the biopharmaceutical company’s stock worth $8,391,000 after acquiring an additional 68,776 shares in the last quarter. Legal & General Group Plc raised its stake in Sage Therapeutics by 9.5% during the first quarter. Legal & General Group Plc now owns 10,748 shares of the biopharmaceutical company’s stock worth $755,000 after acquiring an additional 934 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Sage Therapeutics by 10.8% during the first quarter. Vanguard Group Inc. now owns 2,691,275 shares of the biopharmaceutical company’s stock worth $191,269,000 after acquiring an additional 261,759 shares in the last quarter.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.